Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. Cancer J Clin. 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95:S161–S192.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. JCO. 2002;20:1248–1259.
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med. 1993;329:1550–1559.
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. JCO. 2014;32:1302–1308.
   PubMed Web of Science ®Google Scholar
• Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435–1443.
   PubMed Web of Science ®Google Scholar
• Hilal Z, Schultheis B, Hartmann F, et al. What characterizes long-term survivors of recurrent ovarian cancer? case report and review of the literature. AR. 2016;36:5365–5371.
   Google Scholar
• Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol. 1990;38:203–209.
   PubMed Web of Science ®Google Scholar
• Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol. 2012;19:4059–4067.
   PubMed Web of Science ®Google Scholar
• Tentes AA, Mirelis CG, Markakidis SK, et al. Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures. Int J Gynecol Cancer. 2006;16:490–495.
   PubMed Web of Science ®Google Scholar
• Kaern J, Aghmesheh M, Nesland JM, et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer. 2005;15:1014–1022.
   PubMed Web of Science ®Google Scholar
• Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–274.
   PubMed Web of Science ®Google Scholar
• Ceelen WP, Van Nieuwenhove Y, Van Belle S, et al. Cytoreduction and hyperthermic intraperitoneal chemoperfusion in women with heavily pretreated recurrent ovarian cancer. Ann Surg Oncol. 2012;19:2352–2359.
   PubMed Web of Science ®Google Scholar
• Cotte E, Glehen O, Mohamed F, et al. Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg. 2007;31:1813–1820.
   PubMed Web of Science ®Google Scholar
• Galaal K, Naik R, Bristow RE, et al. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2010;(6):CD007822.
   PubMed Web of Science ®Google Scholar
• Kajiyama H, Shibata K, Mizuno M, et al. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type?. Int J Gynecol Cancer. 2012;22:394–399.
   PubMed Web of Science ®Google Scholar
• Mulier S, Claes JP, Dierieck V, et al. Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18:3793–3803.
   PubMed Web of Science ®Google Scholar
• Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol. 2010;101:244–250.
   PubMed Web of Science ®Google Scholar
• Fagotti A, Costantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122:221–225.
   PubMed Web of Science ®Google Scholar
• van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–240.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–1575.
   PubMed Web of Science ®Google Scholar
• Didelot C, Lanneau D, Brunet M, et al. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. CMC. 2007;14:2839–2847.
   PubMed Web of Science ®Google Scholar
• Hegyi G, Szigeti GP, Szasz A. Hyperthermia versus oncothermia: cellular effects in complementary cancer therapy. Evid Based Complement Alternat Med. 2013;2013:1.
   Web of Science ®Google Scholar
• Krag KJ, Canellos GP, Griffiths CT, et al. Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol. 1989;34:88–93.
   PubMed Web of Science ®Google Scholar
• Goff BA, Muntz HG, Greer BE, et al. Oncogene expression: long-term compared with short-term survival in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 1998;92:88–93.
   PubMed Web of Science ®Google Scholar
• Fleisch MC, Pantke P, Beckmann MW, et al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol. 2007;95:476–484.
   PubMed Web of Science ®Google Scholar
• Winter WE, 3rd, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. JCO. 2007;25:3621–3627.
   PubMed Web of Science ®Google Scholar
• Grossi E, Noli S, Scarfone G, et al. Ten years survival of FIGO stage IIIC epithelial ovarian cancer cases due to lymph node metastases only. Eur J Gynaecol Oncol. 2012;33:615–616.
   PubMed Web of Science ®Google Scholar
• Barlin JN, Jelinic P, Olvera N, et al. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. Gynecol Oncol. 2013;128:512–517.
   PubMed Web of Science ®Google Scholar
• Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11:3686–3696.
   PubMed Web of Science ®Google Scholar
• Partheen K, Levan K, Osterberg L, et al. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer. 2006;42:2846–2854.
   PubMed Web of Science ®Google Scholar
• Stalberg K, Crona J, Razmara M, et al. An integrative genomic analysis of formalin fixed paraffin-embedded archived serous ovarian carcinoma comparing long-term and short-term survivors. Int J Gynecol Cancer. 2016;26:1027–1032.
   PubMed Web of Science ®Google Scholar
• Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. JCO. 2008;26:20–25.
   PubMedGoogle Scholar
• Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011;22:1127–1132.
   PubMed Web of Science ®Google Scholar
• Tan DS, Rothermundt C, Thomas K, et al. “BRCAness” syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. JCO. 2008;26:5530–5536.
   PubMed Web of Science ®Google Scholar
• Petrillo M, De Iaco P, Cianci S, et al. Long-term survival for platinum-sensitive recurrent ovarian cancer patients treated with secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2016;23:1660–1665.
   PubMed Web of Science ®Google Scholar
• Iwase H, Takada T, Iitsuka C, et al. Clinical features of long-term survivors of recurrent epithelial ovarian cancer. Int J Clin Oncol. 2015;20:143–149.
   PubMed Web of Science ®Google Scholar
• Albuquerque K, Patel M, Liotta M, et al. Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer. Int J Gynecol Cancer. 2016;26:655–660.
   PubMed Web of Science ®Google Scholar
• Stephens RJ, Bailey AJ, Machin D. Long-term survival in small cell lung cancer: the case for a standard definition. Medical Research Council Lung Cancer Working Party. Lung Cancer. 1996;15:297–309.
   PubMed Web of Science ®Google Scholar
• Rubin SC, Randall TC, Armstrong KA, et al. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999;93:21–24.
   PubMed Web of Science ®Google Scholar
• Hoppenot C, Eckert MA, Tienda SM, et al. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2017;148(1):204–212.
   PubMed Web of Science ®Google Scholar
• Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. JCO. 2003;21:799–806.
   PubMed Web of Science ®Google Scholar